FHTX
vs
S&P 500
FHTX
S&P 500
Over the past 12 months, FHTX has underperformed S&P 500, delivering a return of +6% compared to the S&P 500's +14% growth.
Stocks Performance
FHTX vs S&P 500
Performance Gap
FHTX vs S&P 500
Performance By Year
FHTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Foghorn Therapeutics Inc.
Glance View
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.